Navigation Links
Bionovo Announces Second Quarter 2009 Highlights and Financial Results
Date:8/10/2009

y and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Financial Tables on Following Pages


                                    Bionovo, Inc.
                            (A Development Stage Company)
                        Consolidated Statements of Operations
                 (Unaudited, in thousands, except per share amounts)

                                                                 Accumulated
                                                              from February 1,
                                                               2002 (Date of
                         Three months ended    Six months ended  inception) to
                                June 30,             June 30,      June 30,
                         ------------------     ---------------- ------------
                             2009      2008      2009      2008      2009
                             ----      ----      ----      ----      ----

    Revenues                   $7        $-        $7        $-      $899

    Operating expenses:
      Research and
'/>"/>
SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... 25, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ... John H. Johnson as Chief Executive Officer, effective January 31, ... Savient,s board of directors. Mr. Johnson brings significant ... a Senior Vice President of Eli Lilly and Company and ...
... recently launched eCS Inpatient EHR V1.2 (eCS), the first ... medium hospitals. eCS,s uniqueness is the tight linkage of ... a single web-based software solution. The solution is offered ... simplified deployment. "eCS is an affordable solution ...
Cached Medicine Technology:Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 2Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 3Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 4eCareSoft Launches Comprehensive EHR for Small & Medium Hospitals 2
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
(Date:4/17/2014)... 17, 2014 By discovering a new mechanism that ... stroke, researchers at UC Irvine and the Salk Institute ... limit or prevent stroke-induced brain damage. , A complex ... of death and primary reason for disability in the ... stroke and lets blood-borne material into the brain, causing ...
Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... of New England and the Rhode Island House and senate ... multiple sclerosis, AIDS and other chronic // diseases ... these patients. The new bill allows patients to have possession ... marijuana was illegal. But, the Governor Carcieri still oppose the ...
... has a counter which states that heart conditions became worse ... heart disease when they were fed a soy diet. ... mice carried and were severely affected by the soy diet. ... failure. This study was done by University of Colorado at ...
... a pilot study by The New Women's Health Initiative ... fat but rich in carbohydrates results in negligible weight ... between weight alterations in postmenopausal women Vis a Vis ... in this category were advised to reduce the fat ...
... was misled about the dangers of taking cannabis when the ... than a year ago, the British Home Secretary admits today. ... decision taken by his predecessor, David Blunkett, Charles Clarke said ... link between cannabis and mental illness. He made these damning ...
... in the offing for abdominal aortic aneurysm, a blood vessel condition ... ,This condition, a swelling // in the ... bursts, accounts for 1.36% of deaths in men over 65 in ... for men in that age group, Pulse magazine says. ...
... customers to trap doctors who conduct sex determination tests for ... State’s sex ratio is less than 800 females for every ... would be paid up to Rs.5,000 to help nab diagnostic ... Family Welfare Secretary D.S. Guru said field officers of the ...
Cached Medicine News:Health News:UK public misled over downgrading cannabis: Govt 2Health News:Experts urging artery screening in the UK 2
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
... For use as a ... detecting IgG antibody to Toxoplasma ... to rubella virus (rubella IgG), ... IgG) and IgG antibody to ...
... VITROS Anti-HCV assay is the third diagnostic,hepatitis ... Drug,Administration capable of being run in a ... with Intellicheck. Now the laboratory staff,can run ... of more than 27 assays, and provide ...
... For use as a quality ... immunoglobulin M (IgM) antibodies to ... IgM), IgM antibodies to hepatitis ... B e antigen (HBeAg) and ...
Medicine Products: